NASDAQ:CTSO Cytosorbents - CTSO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. $3.05 +0.02 (+0.66%) (As of 02/2/2023 09:47 AM ET) Add Compare Share Share Today's Range$3.05▼$3.1050-Day Range$1.03▼$3.0352-Week Range$1.03▼$4.15Volume1,871 shsAverage Volume102,917 shsMarket Capitalization$133.10 millionP/E RatioN/ADividend YieldN/APrice Target$5.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cytosorbents MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.5% Upside$5.75 Price TargetShort InterestHealthy1.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 6 Articles This WeekInsider TradingAcquiring Shares$25,389 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.83) to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector500th out of 1,030 stocksSurgical & Medical Instruments Industry53rd out of 105 stocks 3.5 Analyst's Opinion Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.75, Cytosorbents has a forecasted upside of 88.5% from its current price of $3.05.Amount of Analyst CoverageCytosorbents has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.42% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cytosorbents has recently increased by 3.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CTSO. Previous Next 2.5 News and Social Media Coverage News SentimentCytosorbents has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cytosorbents this week, compared to 1 article on an average week.Search Interest5 people have searched for CTSO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cytosorbents to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,389.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 34.04% of the stock of Cytosorbents is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.83) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -3.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Cytosorbents (NASDAQ:CTSO) StockCytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Read More Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address CTSO Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comCytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 RevenueJanuary 29, 2023 | finance.yahoo.comCytosorbents Corporation's (NASDAQ:CTSO) market cap touched US$103m last week, benefiting both individual investors who own 52% as well as institutionsFebruary 2, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 29, 2023 | americanbankingnews.comAnalyzing Cytosorbents (NASDAQ:CTSO) & DarioHealth (NASDAQ:DRIO)January 27, 2023 | americanbankingnews.comStockNews.com Downgrades Cytosorbents (NASDAQ:CTSO) to SellJanuary 23, 2023 | finance.yahoo.comCytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T TrialJanuary 17, 2023 | finance.yahoo.comCytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory AffairsJanuary 12, 2023 | finance.yahoo.comCan Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth?February 2, 2023 | Investing Trends (Ad)Solar Industry at Start of Long Bull Run?The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.January 10, 2023 | ca.finance.yahoo.comCytosorbents Corporation (CTSO)December 29, 2022 | finance.yahoo.comCytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan AgreementDecember 21, 2022 | finance.yahoo.comCytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without ModificationsNovember 21, 2022 | msn.comCytoSorbents's Return On Capital Employed OverviewNovember 17, 2022 | finance.yahoo.comThese Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under ThreatNovember 14, 2022 | finance.yahoo.comCytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients EnrolledNovember 9, 2022 | finance.yahoo.comCytosorbents Third Quarter 2022 Earnings: Misses ExpectationsNovember 3, 2022 | finance.yahoo.comCytoSorbents Reports Third Quarter 2022 Financial and Operational ResultsNovember 3, 2022 | finance.yahoo.comCytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue EstimatesNovember 2, 2022 | finance.yahoo.com'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. HospitalsOctober 31, 2022 | finance.yahoo.comNational Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine PlasmaOctober 27, 2022 | finance.yahoo.comCytoSorbents to Report Third Quarter 2022 Operating and Financial ResultsOctober 25, 2022 | finance.yahoo.comBreakeven On The Horizon For Cytosorbents Corporation (NASDAQ:CTSO)October 18, 2022 | uk.investing.comWhy fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving Premarket By Benzinga - Investing.com UKOctober 18, 2022 | benzinga.comWhy fuboTV Shares Are Trading Higher By 11%; Here Are 22 Stocks Moving Premarket - Adamis Pharmaceuticals - BenzingaOctober 13, 2022 | finance.yahoo.comCytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting - Yahoo FinanceOctober 12, 2022 | finance.yahoo.comCytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual MeetingOctober 10, 2022 | fortune.comThe companies combining profit and purpose on Fortune’s Change the World list - FortuneSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address CTSO Company Calendar Last Earnings11/04/2021Today2/02/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTSO CUSIPN/A CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees221Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.75 High Stock Price Forecast$6.00 Low Stock Price Forecast$5.50 Forecasted Upside/Downside+88.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,560,000.00 Net Margins-114.61% Pretax Margin-116.65% Return on Equity-80.80% Return on Assets-54.01% Debt Debt-to-Equity RatioN/A Current Ratio3.20 Quick Ratio2.85 Sales & Book Value Annual Sales$43.17 million Price / Sales3.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.44 per share Price / Book2.12Miscellaneous Outstanding Shares43,640,000Free Float40,581,000Market Cap$133.10 million OptionableOptionable Beta0.76 Key ExecutivesDr. Phillip P. Chan M.D. (Age 53)Ph.D., CEO & Director Comp: $667.47kMr. Vincent J. Capponi M.S. (Age 65)MS, Pres & COO Comp: $539.29kMs. Kathleen P. Bloch CPA (Age 68)CPA, M.B.A., MBA, CFO & Sec. Comp: $462.11kDr. Efthymios N. Deliargyris FACC (Age 54)FESC, FSCAI, M.D., Chief Medical Officer Comp: $521.61kMs. Terri Anne Powers M.B.A.VP of Investor Relations & Corp. CommunicationsDr. Christian Steiner M.D.Exec. VP of Sales & MarketingMr. Christopher Cramer MBAMS, VP of Bus. Devel.Dr. Robert H. Bartlett M.D. (Age 84)Co-Chairman of Cardiac Surgery Advisory Board & Consultant More ExecutivesKey CompetitorsAkiliNASDAQ:AKLIHealth Sciences Acquisitions Co. 2NASDAQ:HSAQPulse BiosciencesNASDAQ:PLSEApyx MedicalNASDAQ:APYXTitan MedicalNASDAQ:TMDIView All CompetitorsInsiders & InstitutionsSargent Investment Group LLCSold 124,100 shares on 1/31/2023Ownership: 2.255%Eudaimonia Partners LLCBought 9,000 shares on 1/24/2023Ownership: 0.046%Phillip P ChanBought 5,859 shares on 12/8/2022Total: $7,382.34 ($1.26/share)Phillip P ChanBought 14,291 shares on 12/6/2022Total: $18,006.66 ($1.26/share)Avenir CorpBought 149,855 shares on 11/16/2022Ownership: 5.304%View All Insider TransactionsView All Institutional Transactions CTSO Stock - Frequently Asked Questions Should I buy or sell Cytosorbents stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CTSO shares. View CTSO analyst ratings or view top-rated stocks. What is Cytosorbents' stock price forecast for 2023? 1 Wall Street research analysts have issued 12 month price targets for Cytosorbents' shares. Their CTSO share price forecasts range from $5.50 to $6.00. On average, they expect the company's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 89.8% from the stock's current price. View analysts price targets for CTSO or view top-rated stocks among Wall Street analysts. How have CTSO shares performed in 2023? Cytosorbents' stock was trading at $1.55 at the start of the year. Since then, CTSO shares have increased by 95.5% and is now trading at $3.03. View the best growth stocks for 2023 here. When is Cytosorbents' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our CTSO earnings forecast. How were Cytosorbents' earnings last quarter? Cytosorbents Co. (NASDAQ:CTSO) posted its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company earned $9.76 million during the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative net margin of 114.61% and a negative trailing twelve-month return on equity of 80.80%. During the same period last year, the firm posted ($0.02) EPS. What guidance has Cytosorbents issued on next quarter's earnings? Cytosorbents updated its fourth quarter 2022 earnings guidance on Tuesday, January, 31st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $9.40 million-$9.40 million, compared to the consensus revenue estimate of $8.90 million. What is Phillip Chan's approval rating as Cytosorbents' CEO? 11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). What is Cytosorbents' stock symbol? Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO." Who are Cytosorbents' major shareholders? Cytosorbents' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (2.26%), Eudaimonia Partners LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Al Kraus, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View institutional ownership trends. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Cytosorbents' stock price today? One share of CTSO stock can currently be purchased for approximately $3.03. How much money does Cytosorbents make? Cytosorbents (NASDAQ:CTSO) has a market capitalization of $132.23 million and generates $43.17 million in revenue each year. The medical research company earns $-24,560,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. How many employees does Cytosorbents have? The company employs 221 workers across the globe. How can I contact Cytosorbents? Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The official website for the company is www.cytosorbents.com. The medical research company can be reached via phone at (732) 329-8885, via email at avogel@cytosorbents.com, or via fax at 732-329-8650. This page (NASDAQ:CTSO) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.